The role and clinical value of EUS in a multimodality esophageal carcinoma staging program with CT and positron emission tomography

被引:102
作者
Pfau, Patrick R.
Perlman, Scott B.
Stanko, Peter
Frick, Terrence J.
Gopal, Deepak V.
Said, Adnan
Zhang, Zhengjun
Weigel, Tracey
机构
[1] Univ Wisconsin, Sch Med, Sect Gastroenterol & Hepatol, Dept Med, Madison, WI 53792 USA
[2] Univ Wisconsin, Sch Med, Dept Radiol, Madison, WI 53792 USA
[3] Univ Wisconsin, Sch Med, Dept Biostat, Madison, WI 53792 USA
[4] Univ Wisconsin, Sch Med, Dept Thorac Surg, Madison, WI 53792 USA
关键词
D O I
10.1016/j.gie.2006.12.015
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background: EUS, CT, and positron emission tomography (PET) have all been used in the preoperative staging of esophageal cancer separately or in various combinations. Objective: Our purpose was to determine the value and role of EUS when used in conjunction with CT and PET imaging in staging cancer of the esophagus and gastroesophageal junction. Design: Retrospective single-center clinical trial. Setting: Academic tertiary care center. Patients: Data were examined for 56 patients who concomitantly underwent examination with EUS, CT, and PET in a multimodality staging program. Main Outcome Measurements: EUS, CT, and PET were examined for their ability to detect the primary tumor, local tumor stage, locoregional adenopathy, and distant metastases. With use of surgical resection as baseline therapy, the frequency at which EUS, CT, and PET affected and changed management was examined. Results: EUS is the only imaging test that identified all primary tumors and provided tumor staging. EUS identified a significantly greater number of patients (58.9%) with locoregional nodes than did CT (26.8%), P = .0006, or PET (37.5%), P = .02. CT identified 14.3% and PET identified 26.8% of patients with distant metastases. With CT alone, 15.2% of patients were not taken to surgery, whereas PET affected management by preventing surgery because of metastatic disease in 28.3% of patients. EUS changed management by guiding the need for neoadjuvant therapy in 34.8% of patients. Limitations: Retrospective study, nonblinded study, lack of pathologic reference standard. Conclusion: The primary strength of EUS in a multimodality staging strategy is in identifying patients with locally advanced disease and guiding the need for preoperative neoadjuvant therapy. EUS is not suited to determine resectability of esophageal cancer alone and thus is most effective when used in conjunction with other imaging tests such as CT and PET.
引用
收藏
页码:377 / 384
页数:8
相关论文
共 37 条
  • [11] Ginsberg G, 2002, SLEISENGER FORDTRANS, P647
  • [12] Transthoracic versus transhiatal resection for carcinoma of the esophagus: A meta-analysis
    Hulscher, JBF
    Tijssen, JGP
    Obertop, H
    van Lanschot, JJB
    [J]. ANNALS OF THORACIC SURGERY, 2001, 72 (01) : 306 - 313
  • [13] The incremental effect of positron emission tomography on diagnostic accuracy in the initial staging of esophageal carcinoma
    Kato, H
    Miyazaki, T
    Nakajima, M
    Takita, J
    Kimura, H
    Faried, A
    Sohda, M
    Fukai, Y
    Masuda, N
    Fukuchi, M
    Manda, R
    Ojima, H
    Tsukada, K
    Kuwano, H
    Oriuchi, N
    Endo, K
    [J]. CANCER, 2005, 103 (01) : 148 - 156
  • [14] Histopathologic validation of lymph node staging with FDG-PET scan in cancer of the esophagus and gastroesophageal junction - A prospective study based on primary surgery with extensive lymphadenectomy
    Lerut, T
    Flamen, P
    Ectors, N
    Van Cutsem, E
    Peeters, M
    Hiele, M
    De Wever, W
    Coosemans, W
    Decker, G
    De Leyn, P
    Deneffe, G
    Van Raemdonck, D
    Mortelmans, L
    [J]. ANNALS OF SURGERY, 2000, 232 (06) : 743 - 751
  • [15] The role of PET scan in the preoperative management of oesophageal cancer
    Liberale, G
    Van Laethem, JL
    Gay, F
    Goldman, S
    Nagy, N
    Coppens, E
    Gelin, M
    Nakadi, IE
    [J]. EJSO, 2004, 30 (09): : 942 - 947
  • [16] EUS in the evaluation of esophageal carcinoma
    Mallery, S
    Van Dam, J
    [J]. GASTROINTESTINAL ENDOSCOPY, 2000, 52 (06) : S6 - S11
  • [17] Mallery S, 1999, CANCER-AM CANCER SOC, V86, P764, DOI 10.1002/(SICI)1097-0142(19990901)86:5<764::AID-CNCR10>3.0.CO
  • [18] 2-W
  • [19] EUS predictors of long-term survival in esophageal carcinoma
    Pfau, PR
    Ginsberg, GG
    Lew, RJ
    Brensinger, CM
    Kochman, ML
    [J]. GASTROINTESTINAL ENDOSCOPY, 2001, 53 (04) : 463 - 469
  • [20] COMBINED THERAPIES FOR SQUAMOUS-CELL CARCINOMA OF THE ESOPHAGUS, A SOUTHWEST ONCOLOGY GROUP-STUDY (SWOG-8037)
    POPLIN, E
    FLEMING, T
    LEICHMAN, L
    SEYDEL, HG
    STEIGER, Z
    TAYLOR, S
    VANCE, R
    STUCKEY, WJ
    RIVKIN, SE
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1987, 5 (04) : 622 - 628